Home » Thought Leadership » Infographics » KYMRIAH and TRELEGY Become the…

KYMRIAH and TRELEGY Become the First Drugs to Undergo Japan’s New CEA System

June 17, 2021


Written by: Esmee Scriven Maaz Rafique Shinkyu Park

On March 31, Japan’s Ministry of Health, Labor and Welfare (MHLW) published the results of the Cost-Effectiveness Assessments (CEAs) for KYMRIAH and TRELEGY, the first two products to have completed the CEAs since the system was formally introduced in April 2019.

In this infographic, CBPartners offers insights into the calculation process as well as the key takeaways from the first CEA reports.

Read the infographic here.


If you are interested in reading more about the Asia-Pacific landscape, read related posts in the Center of Excellence team’s thought leadership channel, or find out more about the work we do.